Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4

Antiviral Research

Volumn 129, Issue , 2016, Pages 93-98

  Warfield, Kelly L ^a,g   Plummer, Emily M ^b   Sayce, Andrew C ^c   Alonzi, Dominic S ^c   Tang, William ^b   Tyrrell, Beatrice E ^c   Hill, Michelle L ^c   Caputo, Alessandro T ^c   Killingbeck, Sarah S ^d   Beatty, P Robert ^d   Harris, Eva ^d   Iwaki, Ren ^e   Kinami, Kyoko ^e   Ide, Daisuke ^e   Kiappes, J L ^c   Kato, Atsushi ^e   Buck, Michael D ^b   King, Kevin ^b   Eddy, William ^b   Khaliq, Mansoora ^a   Sampath, Aruna ^a   Treston, Anthony M ^a   Dwek, Raymond A ^c   Enterlein, Sven G ^f   Miller, Joanna L ^c   Zitzmann, Nicole ^c   Ramstedt, Urban ^g   Shresta, Sujan ^b   more..

^a Emergent Virology LLC   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TOYAMA   (Japan)

^f Integrated BioTherapeutics   (United States)

^g Unither Virology LLC   (United States)

Author keywords

Antibody dependent enhancement; Antiviral; Dengue; Glucosidase; Iminosugar; UV 4B

Indexed keywords

ALPHA GLUCOSIDASE; ANTIVIRUS AGENT; GLUCOSIDASE; GLYCOSPHINGOLIPID; IMINOSUGAR; N (9' METHOXYNONYL) 1 DEOXYNOJIRIMYCIN HYDROCHLORIDE; UNCLASSIFIED DRUG; 1 DEOXYNOJIRIMYCIN; GLYCOSIDASE INHIBITOR; INTERFERON RECEPTOR; INTERFERON RECEPTOR, TYPE II; N-(9-METHOXYNONYL)-1-DEOXYNOJIRIMYCIN; NEW DRUG; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT ENHANCEMENT; ANTIVIRAL ACTIVITY; ARTICLE; BHK CELL LINE; CELL LYSATE; COMPARATIVE STUDY; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PLAQUE ASSAY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SELECTIVITY INDEX; STEREOCHEMISTRY; SURVIVAL; SURVIVAL RATE; THERAPEUTIC INDEX; TREATMENT DURATION; VERO CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CELL CULTURE; CHEMISTRY; CHLOROCEBUS AETHIOPS; CLINICAL TRIAL (TOPIC); DEFICIENCY; DENGUE VIRUS; DISEASE MODEL; DRUG EFFECTS; ENDOPLASMIC RETICULUM; ENZYMOLOGY; IC50; METABOLISM; MONOCYTE; SEROTYPE; SEVERE DENGUE; VIROLOGY;

1-DEOXYNOJIRIMYCIN; ALPHA-GLUCOSIDASES; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; ANTIVIRAL AGENTS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CLINICAL TRIALS AS TOPIC; DENGUE VIRUS; DISEASE MODELS, ANIMAL; DRUGS, INVESTIGATIONAL; ENDOPLASMIC RETICULUM; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MONOCYTES; RECEPTORS, INTERFERON; SEROGROUP; SEVERE DENGUE; VERO CELLS;

EID: 84960364160     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.03.001     Document Type: Article

References (32)

1. D.S. Alonzi, D.C. Neville, R.H. Lachmann, R.A. Dwek, and T.D. Butters Glucosylated free oligosaccharides are biomarkers of endoplasmic- reticulum alpha-glucosidase inhibition Biochem. J. 409 2008 571 580
2. N. Asano, M. Nishida, A. Kato, H. Kizu, K. Matsui, Y. Shimada, T. Itoh, M. Baba, A.A. Watson, R.J. Nash, P.M. Lilley, D.J. Watkin, and G.W. Fleet Homonojirimycin isomers and N-alkylated homonojirimycins: structural and conformational basis of inhibition of glycosidases J. Med. Chem. 41 1998 2565 2571
3. S.J. Balsitis, K.L. Williams, R. Lachica, D. Flores, J.L. Kyle, E. Mehlhop, S. Johnson, M.S. Diamond, P.R. Beatty, and E. Harris Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification PLoS Pathog. 6 2010 e1000790
4. S. Bhatt, P.W. Gething, O.J. Brady, J.P. Messina, A.W. Farlow, C.L. Moyes, J.M. Drake, J.S. Brownstein, A.G. Hoen, O. Sankoh, M.F. Myers, D.B. George, T. Jaenisch, G.R. Wint, C.P. Simmons, T.W. Scott, J.J. Farrar, and S.I. Hay The global distribution and burden of dengue Nature 496 2013 504 507
5. J. Chang, T.M. Block, and J.T. Guo Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions Antivir. Res. 99 2013 251 260
6. B.A. Coller, D.E. Clements, T. Martyak, M. Yelmene, M. Thorne, and D.E. Parks Advances in flavivirus vaccine development IDrugs 13 2010 880 884
7. D. Durantel, N. Branza-Nichita, S. Durantel, R.A. Dweek, and N. Zitzmann The bovine viral diarrhoea virus: a model for the study of antiviral molecules interfering with N-glycosylation and folding of envelope glycoprotein Adv. Exp. Med. Biol. 564 2005 5 6
8. R.A. Dwek, T.D. Butters, F.M. Platt, and N. Zitzmann Targeting glycosylation as a therapeutic approach. Nature reviews Drug Discov. 1 2002 65 75
9. A.F. Glawar, D. Best, B.J. Ayers, S. Miyauchi, S. Nakagawa, M. Aguilar-Moncayo, J.M. Garcia Fernandez, C. Ortiz Mellet, E.V. Crabtree, T.D. Butters, F.X. Wilson, A. Kato, and G.W. Fleet Scalable syntheses of both enantiomers of DNJNAc and DGJNAc from glucuronolactone: the effect of N-alkylation on hexosaminidase inhibition Chemistry 18 2012 9341 9359
10. D.J. Gubler Dengue and dengue hemorrhagic fever Clin. Microbiol. Rev. 11 1998 480 496
11. S.B. Halstead Dengue Lancet 370 2007 1644 1652
12. NCT02061358: Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects. U.S. National Institutes of Health https://clinicaltrials.gov/ct2/show/NCT02061358.
13. J.G. Julander, S.T. Perry, and S. Shresta Important advances in the field of anti-dengue virus research Antivir. Chem. Chemother. 21 2011 105 116
14. T. Laue, P. Emmerich, and H. Schmitz Detection of dengue virus RNA in patients after primary or secondary dengue infection by using the TaqMan automated amplification system J. Clin. Microbiol. 37 1999 2543 2547
15. A. Mehta, N. Zitzmann, P.M. Rudd, T.M. Block, and R.A. Dwek Alpha-glucosidase inhibitors as potential broad based anti-viral agents FEBS Lett. 430 1998 17 22
16. D.C. Neville, V. Coquard, D.A. Priestman, D.J. te Vruchte, D.J. Sillence, R.A. Dwek, F.M. Platt, and T.D. Butters Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling Anal. Biochem. 331 2004 275 282
17. S. Orozco, M.A. Schmid, P. Parameswaran, R. Lachica, M.R. Henn, R. Beatty, and E. Harris Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor J. Gen. Virol. 93 2012 2152 2157
18. S.T. Perry, M.D. Buck, E.M. Plummer, R.A. Penmasta, H. Batra, E.J. Stavale, K.L. Warfield, R.A. Dwek, T.D. Butters, D.S. Alonzi, S.M. Lada, K. King, B. Klose, U. Ramstedt, and S. Shresta An iminosugar with potent inhibition of dengue virus infection in vivo Antivir. Res. 98 2013 35 43
19. F.M. Platt, G.R. Neises, R.A. Dwek, and T.D. Butters N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis J. Biol. Chem. 269 1994 8362 8365
20. F.M. Platt, G.R. Neises, G.B. Karlsson, R.A. Dwek, and T.D. Butters N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing J. Biol. Chem. 269 1994 27108 27114
21. E. Plummer, M.D. Buck, M. Sanchez, J.A. Greenbaum, J. Turner, R. Grewal, B. Klose, A. Sampath, K.L. Warfield, B. Peters, U. Ramstedt, and S. Shresta Dengue virus evolution under a host-targeted antiviral J. Virol. 89 2015 5592 5601
22. E.M. Plummer, and S. Shresta Mouse models for dengue vaccines and antivirals J. Immunol. methods 410 2014 34 38
23. A.P. Rathore, P.N. Paradkar, S. Watanabe, K.H. Tan, C. Sung, J.E. Connolly, J. Low, E.E. Ooi, and S.G. Vasudevan Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model Antivir. Res. 92 2011 453 460
24. M.A. Sadat, S. Moir, T.W. Chun, P. Lusso, G. Kaplan, L. Wolfe, M.J. Memoli, M. He, H. Vega, L.J. Kim, Y. Huang, N. Hussein, E. Nievas, R. Mitchell, M. Garofalo, A. Louie, D.C. Ireland, C. Grunes, R. Cimbro, V. Patel, G. Holzapfel, D. Salahuddin, T. Bristol, D. Adams, B.E. Marciano, M. Hegde, Y. Li, K.R. Calvo, J. Stoddard, J.S. Justement, J. Jacques, D.A. Long Priel, D. Murray, P. Sun, D.B. Kuhns, C.F. Boerkoel, J.A. Chiorini, G. Di Pasquale, D. Verthelyi, and S.D. Rosenzweig Glycosylation, hypogammaglobulinemia, and resistance to viral infections N. Engl. J. Med. 370 2014 1615 1625
25. A.C. Sayce, D. Alonzi, S.S. Killingbeck, B.E. Tyrrell, M.L. Hill, A.T. Caputo, R. Iwaki, K. Kinami, A. Kamori, J.L. Knappes, P.R. Beatty, A. Kato, E. Harris, R.A. Dwek, J.L. Miller, and N. Zitzmann Iminosugars inhibit dengue virus production via inhibition of alpha-glucosidases - not glycoprotein processing enzymes PLoS negl. Trop. Dis. March 16, 2016 (in this issue)
26. A.C. Sayce, J.L. Miller, and N. Zitzmann Targeting a host process as an antiviral approach against dengue virus Trends Microbiol. 18 2010 323 330
27. W. Schul, W. Liu, H.Y. Xu, M. Flamand, and S.G. Vasudevan A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs J. Infect. Dis. 195 2007 665 674
28. E.J. Stavale, H. Vu, A. Sampath, U. Ramstedt, and K.L. Warfield In vivo therapeutic protection against influenza A (H1N1) oseltamivir-sensitive and resistant viruses by the iminosugar UV-4 PLoS One 10 2015 e0121662
29. W.W. Tang, R. Grewal, and S. Shresta Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models Curr. Opin. Virol. 13 2015 61 66
30. K.L. Warfield, E. Plummer, D.S. Alonzi, G.W. Wolfe, A. Sampath, T. Nguyen, T.D. Butters, S.G. Enterlein, E.J. Stavale, S. Shresta, and U. Ramstedt A novel iminosugar UV-12 with activity against the diverse viruses influenza and dengue (novel iminosugar antiviral for influenza and dengue) Viruses 7 2015 2404 2427
31. S. Watanabe, A.P. Rathore, C. Sung, F. Lu, Y.M. Khoo, J. Connolly, J. Low, E.E. Ooi, H.S. Lee, and S.G. Vasudevan Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial Antivir. Res. 96 2012 32 35
32. R.M. Zellweger, and S. Shresta Mouse models to study dengue virus immunology and pathogenesis Front. Immunol. 5 2014 151